OR WAIT 15 SECS
DSM Sinochem Pharmaceuticals has filed a lawsuit against CSPC Pharmaceutical Group, Inner Mongolia Changsheng Pharmaceutical Company, and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) for infringement of its amoxicillin patent.
On Oct. 9, 2017, DSM Sinochem Pharmaceuticals (DSP), a company that specializes in the production and commercialization of antibiotics and antifungals, announced that its subsidiary, DSM Sinochem Pharmaceuticals Netherlands B.V, has filed a patent infringement lawsuit against CSPC Pharmaceutical Group, Inner Mongolia Changsheng Pharmaceutical Company, and CSPC Zhangnuo Pharmaceutical (Shijiazhuang) Company in the District Court of The Hague, Afdeling Handel (commercial division), Netherlands, for patent infringement of the Dutch part of European patent number 1,610,766 B1.
The patent, which is owned by DSP, specifies procedures for the production of amoxicillin trihydrate with low free-water content. DSP seeks payment for damages and a permanent injunction to prevent the infringing manufacture, use, importation, and sale of CSPC’s amoxicillin, and/or any drug product that uses the API, in the Netherlands.
“DSP has a world class intellectual property (IP) portfolio relating to our innovative, sustainable, and environmental friendly amoxicillin technology”, said Karl Rotthier, CEO at DSP, in a company press release. “After having previously filed patent litigation against Sinopharm Weiqida Pharmaceutical for patent infringement in India and the Netherlands in January 2017, DSP will continue to rigorously enforce its IP assets worldwide against any additional potential infringers as it continues to invest in its innovative R&D programs directed to enzymatic, sustainable antimicrobials and statins.”
DSP Netherlands B.V is set to attend 2017 CPhI Worldwide from October 24–26, 2017 in Messe Frankfurt, Germany in the API zone at stand 80G81.
Source: DSM Sinochem Pharmaceuticals